| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharmaceutical company/ National Institutes of Health [NIH]) | Year complete | Primary publication | Full study treatment protocol |
|---|---|---|---|---|---|
|
ARCHWAY (A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration) |
418 |
Novartis (NCT03677934) |
2021 |
Holekamp NM, et al. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology (in press). 2021. https://www.aaojournal.org/article/S0161-6420(21)00734-X/fulltext |